0.00
100.00%
-0.1053
After Hours:
.1051
0.1051
+
Nanostring Technologies Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1159 pivot point. If it approaches the $0.0544 support level, significant changes may occur.
Previous Close:
$0.1053
Open:
$0
24h Volume:
0
Market Cap:
$5.07M
Revenue:
$162.47M
Net Income/Loss:
$-166.43M
P/E Ratio:
0.00
EPS:
-3.54
Net Cash Flow:
$-135.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Nanostring Technologies Inc Stock (NSTG) Company Profile
Name
Nanostring Technologies Inc
Sector
Industry
Phone
206-378-6266
Address
530 Fairview Avenue North, Suite 2000, Seattle, WA
Nanostring Technologies Inc Stock (NSTG) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-02-23 | Initiated | UBS | Buy |
Mar-24-22 | Initiated | Canaccord Genuity | Buy |
Jan-06-21 | Upgrade | Cowen | Market Perform → Outperform |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-09-18 | Initiated | UBS | Buy |
Oct-12-17 | Downgrade | Janney | Buy → Neutral |
Apr-20-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-11-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Nanostring Technologies Inc Stock (NSTG) Latest News
Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
S&P 500 Tops 5,000; PepsiCo Posts Upbeat Earnings
Benzinga
Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates
Zacks Investment Research
Nanostring Technologies Inc Stock (NSTG) Financials Data
Nanostring Technologies Inc (NSTG) Revenue 2024
NSTG reported a revenue (TTM) of $162.47 million for the quarter ending September 30, 2023, a +20.09% rise year-over-year.
Nanostring Technologies Inc (NSTG) Net Income 2024
NSTG net income (TTM) was -$166.43 million for the quarter ending September 30, 2023, a -15.03% decrease year-over-year.
Nanostring Technologies Inc (NSTG) Cash Flow 2024
NSTG recorded a free cash flow (TTM) of -$135.74 million for the quarter ending September 30, 2023, a +2.29% increase year-over-year.
Nanostring Technologies Inc (NSTG) Earnings per Share 2024
NSTG earnings per share (TTM) was -$3.53 for the quarter ending September 30, 2023, a -12.42% decline year-over-year.
About Nanostring Technologies Inc
NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.
Cap:
|
Volume (24h):